A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 59,000 shares of CABA stock, worth $425,980. This represents 0.0% of its overall portfolio holdings.

Number of Shares
59,000
Holding current value
$425,980
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$16.79 - $25.38 $990,610 - $1.5 Million
59,000 New
59,000 $1.01 Million
Q2 2023

Aug 11, 2023

SELL
$7.65 - $13.95 $268,515 - $489,645
-35,100 Reduced 31.12%
77,700 $1 Million
Q1 2023

May 12, 2023

SELL
$7.08 - $12.62 $358,248 - $638,572
-50,600 Reduced 30.97%
112,800 $933,000
Q4 2022

Feb 13, 2023

SELL
$1.76 - $9.3 $922,347 - $4.87 Million
-524,061 Reduced 76.23%
163,400 $1.51 Million
Q3 2022

Nov 14, 2022

BUY
$0.63 - $2.05 $222,050 - $722,545
352,461 Added 105.21%
687,461 $447,000
Q2 2022

Aug 12, 2022

BUY
$0.99 - $2.11 $134,244 - $286,116
135,600 Added 68.0%
335,000 $355,000
Q1 2022

May 13, 2022

BUY
$1.68 - $3.92 $334,992 - $781,648
199,400 New
199,400 $405,000
Q3 2021

Nov 12, 2021

SELL
$7.0 - $12.5 $104,300 - $186,250
-14,900 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$7.2 - $11.73 $107,280 - $174,777
14,900 New
14,900 $128,000
Q3 2020

Nov 13, 2020

SELL
$9.71 - $14.41 $596,650 - $885,451
-61,447 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$6.39 - $11.28 $309,576 - $546,482
48,447 Added 372.67%
61,447 $685,000
Q1 2020

May 14, 2020

BUY
$6.0 - $18.67 $78,000 - $242,710
13,000 New
13,000 $95,000

Others Institutions Holding CABA

About Cabaletta Bio, Inc.


  • Ticker CABA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,014,000
  • Market Cap $209M
  • Description
  • Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...
More about CABA
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.